Our extensive experience in health technology assessment (HTA) through providing strategic advice and guiding evidence generation to support submissions to UK HTA bodies, enables us to provide you with a tailored solution to reimbursement and patient access.
NICE recommend...
…the first therapy to treat epidermolysis bullosa (EB)